475111-38-7

Usage

Uses

Given the provided materials, there are no specific applications listed for 4-(4-CHLORO-6-(2-(DIFLUOROMETHYL)-1H-BENZO[D]IMIDAZOL-1-YL)-1,3,5-TRIAZIN-2-YL)MORPHOLINE. However, based on its classification as a morpholine derivative and the commonality of heterocyclic rings in bioactive molecules, potential uses in the pharmaceutical industry could be hypothesized:
Used in Pharmaceutical Industry:
4-(4-CHLORO-6-(2-(DIFLUOROMETHYL)-1H-BENZO[D]IMIDAZOL-1-YL)-1,3,5-TRIAZIN-2-YL)MORPHOLINE could be used as a bioactive molecule for the development of new drugs due to its unique structure and the presence of heterocyclic rings, which are often found in pharmaceutically active compounds. Further research is necessary to explore its specific biological activities and potential therapeutic applications.

InChI:InChI=1/C15H13ClF2N6O/c16-13-20-14(23-5-7-25-8-6-23)22-15(21-13)24-10-4-2-1-3-9(10)19-12(24)11(17)18/h1-4,11H,5-8H2

Upstream product

• 6601-22-5 2,6-Dichloro-4-morpholino-1,3,5-triazine 
• 705-09-9 2-(difluoromethyl)-1H-benzo[d]imidazole 
• 3764-01-0 2,4,6-trichloropyrimidine 
• 95-54-5 1,2-diamino-benzene 

Downstream Products

• 475110-96-4 2-(2-difluoromethylbenzimidazol-1-yl)-4,6-dimorpholino-1,3,5-triazine 
• 1416956-33-6 (S)-2-amino-1-(4-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)piperazin-1-yl)-3-phenylpropan-1-one 
• 1416956-15-4 (S)-tert-butyl (1-(4-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)piperazin-1-yl)-1-oxo-3-phenylpropan-2-yl)carbamate 
• 1416956-34-7 (R)-2-amino-1-(4-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)piperazin-1-yl)-3-phenylpropan-1-one 
• 1416956-36-9 (S)-2-amino-1-(4-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-yl)-6-morpholino-1,3,5-triazin-2-yl)piperazin-1-yl)-3-(4-hydroxyphenyl)propan-1-one 
• 1416956-16-5 (R)-tert-butyl (1-(4-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)piperazin-1-yl)-1-oxo-3-phenylpropan-2-yl)carbamate 
• 1416956-20-1 (S)-tert-butyl (1-(4-(4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-6-morpholino-1,3,5-triazin-2-yl)piperazin-1-yl)-3-(4-hydroxyphenyl)-1-oxopropan-2-yl)carbamate 
• 1261281-14-4 2-(difluoromethyl)-1-[4-(4-morpholinyl)-6-phenoxy-1,3,5-triazin-2-yl]-1H-benzimidazole 
• 1261281-10-0 4-[2-(difluoromethyl)-1H-benzimidazol-1-yl]-6-(4-morpholinyl)-N-phenyl-1,3,5-triazin-2-amine 
• 1359963-04-4 1-[4-({4-[2-(difluoromethyl)-1H-benzimidazol-1-yl]-6-(morpholin-4-yl)-1,3,5-triazin-2-yl}oxy)phenyl]ethanone 
• 1401436-63-2 N-(1-(2-bromophenyl)-2-methylpropan-2-yl)-4-(2-(difluoromethyl)-1H-benzo[d]imidazole-1-yl)-6-morpholino-1,3,5-triazin-2-amine 
• 1401436-62-1 4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-N-(2-(1-phenylcyclopropyl)propan-2-yl)-6-morpholino-1,3,5-triazin-2-amine 
• 1401436-44-9 4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-N-(1-(2-chlorophenyl)-2-methylpropan-2-yl)-6-morpholino-1,3,5-triazin-2-amine 
• 1401436-45-0 4-(2-(difluoromethyl)-1H-benzo[d]imidazol-1-yl)-N-(1-(4-methoxyphenyl)-2-methylpropan-2-yl)-6-morpholino-1,3,5-triazin-2-amine 

Relevant academic research and scientific papers

Discovery of novel PARP/PI3K dual inhibitors with high efficiency against BRCA-proficient triple negative breast cancer

Co-targeting PARP and PI3K by PARP/PI3K dual inhibitors has been recognized as a promising chemotherapeutic strategy for the treatment of triple negative breast cancer (TNBC) in our previous work. To further explore novel and more potent PARP/PI3K dual in

PREPARATION OF A 1,3,5-TRIAZINYL BENZIMIDAZOLE

Described herein is the preparation of a 1,3,5-triazinyl benzimidazole and chemical intermediates used in the synthetic process.

PARP-1 and PI3K double-target inhibitor containing benzofuran

The invention relates to the field of medicinal chemistry, in particular to a PARP-1 and PI3K double-target inhibitor containing a benzofuran structure (I) (the formula I is shown in the description),a preparation method and a medicine composition containing thereof. Proved by a pharmacodynamic test, the PARP-1 and PI3K double-target inhibitor has the anti-tumor effect.

1. 3, 5 - Triazine derivatives and use thereof

The invention relates to novel 1,3,5-triazine derivatives represented by the formula I, and pharmaceutically-acceptable salts, hydrates, solvate, and prodrug thereof; wherein the definitions of substituent R1 and substituent R2 are represented in the description. The invention also relates to a preparation method and an application of the derivatives represented by the formula (I) in antitumor drugs.

NOVEL 1,3,5 -TRIAZINE BASED PI3K INHIBITORS AS ANTICANCER AGENTS AND A PROCESS FOR THE PREPARATION THEREOF

The present invention describes heterocyclic compounds of general Formula 1 and their method of preparation thereof. The present invention describes general Formula 1 which inhibits phosphoinositide 3-kinase (PI3K) and can be used as the anticancer agents

PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS

The invention relates to compounds, and uses of the compounds, that are inhibitors of the enzyme phosphoinositide 3-kinase (PI3K). More particularly the compounds are selective inhibitors of one or more isoforms of PI3K. In particular embodiments the compounds are selective inhibitors of one isoform of PI3K

DUAL MEK/PI3K INHIBITORS AND THERAPEUTIC METHODS USING THE SAME

Dual inhibitors of MEK and PI3K and compositions containing the same are disclosed. Methods of using the dual MEK/PI3K inhibitors in the treatment of diseases and conditions wherein inhibition of MEK and PI3K provides a benefit, like cancers, also are disclosed.

L-aminoacyl-triazine derivatives are isoform-selective PI3Kβ inhibitors that target nonconserved Asp862 of PI3Kβ

A series of aminoacyl-triazine derivatives based upon the pan-PI3K inhibitor ZSTK474 were identified as potent and isoform-selective inhibitors of PI3Kβ. The compounds showed selectivity based upon stereochemistry with l-amino acyl derivatives preferring PI3Kβ, while their d-congeners favored PI3Kδ. The mechanistic basis of this inhibition was studied using site-directed mutants. One Asp residue, D862, was identified as a critical participant in binding to the PI3Kβ-selective inhibitors, distinguishing this class from other reported PI3Kβ-selective inhibitors. The compounds show strong inhibition of cellular Akt phosphorylation and growth of PTEN-deficient MD-MBA-468 cells.

SPIROCYCLIC COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES

The invention relates to new triazines (G=Q=U are N), pyrimidines (two out of G, Q and U are N), and pyridopyrimidines (one of G and U together with R2 forms an anullated pyridine ring) of formula (I) carrying a spirocyclic substituent, wherein E1 is CR4 or N; X1 is CHR4, CH2CH2, NR4, NR4→0, or O; and the other substituents are as defined in the specification. The compounds inhibit phosphoinositide 3-kinase (PI3K), mammalian target of rapamycin (mTOR), DNA-PK and ATM kinase, and may be used as therapeutic agents or diagnostic probes. The invention also relates to methods of using the compounds for treatment of associated pathological conditions.

PIPERAZINOTRIAZINES AS PI3K INHIBITORS FOR USE IN THE TREATMENT ANTIPROLIFERATIVE DISORDERS

The invention relates to compounds of formula (I) R1 is methyl, n-hexyl, aminoethyl, methylaminoethyl, ethylaminoethyl, dimethylaminoethyl, acryloylaminoethyl, methacryloylaminoethyl, methoxyethyl, ethoxyethyl, d-C4-alkyl-sulfonyl, acryloyl, or methacryloyl; or R1 is aminoethyl, acryloyl or acryloylaminoethyl carrying a linker and a tag, and R2 and R3, independently of each other, are hydrogen or CrC4-alkyl, or R2 and R3 together form a methylene or an ethylene bridge; and tautomers, solvates and pharmaceutically acceptable salts thereof. These compounds are effective in preventing or treating a disease or disorder modulated by PI3 kinases and/or mTOR, in particular treating a hyperproliferative disorder.